An antiepileptic agent
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Carisbamate

Item No. 23514

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(1S)-1-(2-chlorophenyl)-1,2-ethanediol, 2-carbamate
CAS Number
194085-75-1
Synonyms
  • JNJ-10234094
  • RWJ 333369
Molecular Formula
C9H10ClNO3
Formula Weight
215.6
Purity
≥98%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMSO: Soluble
SMILES
ClC1=C([C@H](O)COC(N)=O)C=CC=C1
InChi Code
InChI=1S/C9H10ClNO3/c10-7-4-2-1-3-6(7)8(12)5-14-9(11)13/h1-4,8,12H,5H2,(H2,11,13)/t8-/m1/s1
InChi Key
OLBWFRRUHYQABZ-MRVPVSSYSA-N
Shipping & Storage Information
Storage
4°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    500 µg

    $134

    Add

    1 mg

    $240

    Add
    Product Description

    Carisbamate is an antiepileptic agent.1,2 In vivo, administration of carisbamate (10-60 mg/kg) dose-dependently reduces spike and wave discharges in the frontoparietal cortex in a rat model of absence seizures.1 Carisbamate (10 mg/kg) increases latency to the first running episode in the Wistar audiogenic sensitive rat model of convulsive seizures. It also reduces motor seizure frequency in a rat model of spontaneous seizures in a dose-dependent manner.2 Carisbamate blocks Nav1.2 channels (IC50 = 68 μM for rat channels) and inhibits repetitive firing of action potentials in rat hippocampal neurons in a dose-dependent manner.3 It also reduces T-type Ca2+ currents in HEK cells transfected with human recombinant Cav3.1 channels at a concentration of 300 μM.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. François, J., Boehrer, A., and Nehlig, A. Effects of carisbamate (RWJ-333369) in two models of genetically determined generalized epilepsy, the GAERS and the audiogenic Wistar AS. Epilepsia 49(3), 393-399 (2008).

    2. Grabenstatter, H.L., and Dudek, F.E. A new potential AED, carisbamate, substantially reduces spontaneous motor seizures in rats with kainate-induced epilepsy. Epilepsia 49(10), 1787-1794 (2008).

    3. Liu, Y., Yohrling, G.J., Wang, Y., et al. Carisbamate, a novel neuromodulator, inhibits voltage-gated sodium channels and action potential firing of rat hippocampal neurons. Epilepsy Res. 83(1), 66-72 (2009).

    4. Kim, D.Y., Zhang, F.X., Nakanishi, S.T., et al. Carisbamate blockade of T-type voltage-gated calcium channels. Epilepsia 58(4), 617-626 (2017).